Physician profile
Abeba Asefa Abebe
NPI 1487262424
$1,650.26
in general payments reported to CMS, 2019-2025
10 companies · $591 in 2025
The $591 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2023: $203 · 2024: $739 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,532.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $362.89 | 2024-2025 | Krystexxa |
| Genzyme Corporation | $311.32 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $233.25 | 2022-2025 | |
| Abbott Laboratories | $153.43 | 2024 | Freestyle Libre 3 |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Alnylam Pharmaceuticals INC. | $107.87 | 2025 | Amvuttra |
| Kyowa Kirin, INC. | $95.72 | 2024 | Crysvita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.57 | 2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $88.23 | 2024 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $81.88 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abeba Abebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.